Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Meningococcal Disease, Pregnancy, Infections, Meningococcal
Interventions: Meningococcal quadrivalent CRM-197 conjugate vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Wilmington, North Carolina

Conditions: Suicide, Attempted, Suicide Threat
Interventions: WET-SP, TAU; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Reperfusion Injury, Post Cardiac Arrest Brain Injury
Interventions: LUTICIA - Light Utilization COX-Inhibitory Device); Device
Lead sponsor: Mitovation, Inc; Industry
Eligibility: 48 Hours to 1 Year
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Leukemia
Interventions: cyclosporine, cytarabine, filgrastim, methotrexate, methylprednisolone, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, umbilical cord blood transplantation, Cis-Retinoic acid; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hairy Cell Leukemia, Leukemia, Leukemia, Hairy Cell
Interventions: Vemurafenib, Obinutuzumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 9
States / cities: New Haven, Connecticut • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more

Conditions: Chronic Pain, Opioid Use
Interventions: Opioid Phase; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer - Female
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Non Small Cell Lung Cancer, Lung Cancer
Interventions: erlotinib, Pemetrexed, Cisplatin, Resection; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Thyroid Eye Disease
Interventions: Teprotumumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 8
States / cities: Beverly Hills, California • Los Angeles, California • Miami, Florida + 5 more

Conditions: COVID, Pneumonia, Viral
Interventions: Methylprednisolone; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Gliosarcoma, Newly Diagnosed, Glioblastoma
Interventions: Selinexor, Temozolomide, Generic Radiation therapy (RT), Selective serotonin receptor (5-HT3) antagonists, Olanzapine, Salt tablets, Anti-diarrheal; Drug · Radiation · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
Interventions: Cone-Beam Computed Tomography, Hypofractionated External Beam Radiation Therapy, Questionnaire Administration, Radiation Boost, Whole Breast Irradiation; Procedure · Radiation · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 40 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Arcadia, California • Duarte, California • Irvine, California + 4 more

Conditions: Patients With Spinal Stenosis Indicated for MIS TLIF
Interventions: Erector spinae plane (ESP) block; Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Residual Paralysis, Post Anesthesia
Interventions: Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex; Combination Product
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hearing Loss, Language Impairment
Interventions: Feedback with massed trials, Feedback with spaced trials, No feedback with massed trials, No feedback with spaced trials; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 5 Years to 9 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Survey Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anxiety, Depression, Malignant Neoplasm
Interventions: Interview, Meditation Therapy, Quality-of-Life Assessment, Supportive Care; Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bicuspid Aortic Valve
Interventions: Not listed
Lead sponsor: Boston University; Other
Eligibility: 14 Years to 80 Years
Enrollment: 11,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leiomyoma
Interventions: Dexamethasone, Saline; Drug
Lead sponsor: University of Miami; Other
Eligibility: 20 Years to 50 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Sleep, THC, Marijuana, Cannabis
Interventions: Dronabinol; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 34 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: RAI1 Gene 17P11.2 Deletion+Duplication
Interventions: Electroencephalography/Polysomnography (EEG/PSG), Skin Biopsy, Blood draw; Diagnostic Test · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Month to 80 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Failure
Interventions: LVAD Implant, Aspirin 100mg, Placebo oral tablet; Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 31 more

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Eculizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 2 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Anaheim, California • Los Angeles, California • Panama City, Florida + 8 more

Search by objective public record fields.

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry

Written Exposure Therapy for Suicide Prevention

Light Utilization COX-Inhibitory Device Therapy for Infant Cardiac Arrest (LUTICA Study). The LUCID Device is Used in the Treatment of Ischemic Brain Reperfusion Injury Caused by Cardiac Arrest in Pediatric Patients.

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Neuroimaging of Opioid Phase (OPAL)

Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy

Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

Early Short Course Corticosteroids in COVID-19

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer

ESP Block in MIS Lumbar Spine Surgery

Best Management of Muscle Relaxation- Objective Monitoring

Retrieval Practice for Word Learning for Deaf and Hard of Hearing Children

Evaluation of Satisfaction With Quality of Care on the Palliative Care Unit

Meditation Therapy in Improving Anxiety and Depression in Cancer Patients With Psychosocial Distress

Identification of Genetic Causes of Bicuspid Aortic Valve Disease

Dexamethasone for Post Uterine Artery Embolization Pain

Tetrahydrocannabinol (THC) and Sleep

Clinical and Molecular Biomarker Studies in RAI1 (Retinoic Acid-Induced 1) -Related Disorders

The ARIES HeartMate 3 Pump IDE Study

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients